Case report of neoantigen-targeting peptide vaccine combined with checkpoint inhibitor immunotherapy produced anti-tumor response, demonstrating personalized combination immunotherapy.
Key findingCase report of neoantigen-targeting peptide vaccine combined with checkpoint inhibitor immunotherapy
What the researchers found
Case report of neoantigen-targeting peptide vaccine combined with checkpoint inhibitor immunotherapy produced anti-tumor response, demonstrating personalized combination immunotherapy.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Single pediatric patient with metastatic HCC achieved tumor regression and long-term remission with combined peptide vaccine and checkpoint immunotherapy.
How the study worked
In publication.
Who was studied
Single pediatric patient with metastatic hepatocellular carcinoma
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Case Report: A neoantigen-targeting peptide vaccine combined with checkpoint inhibition induces tumor regression and long-term remission in a pediatric patient with metastatic hepatocellular carcinoma.
Frontiers in immunology, 16, 1674663
Citation
Amorelli, Germano; Rabsteyn, Armin; Maier, Claus-Philipp; Trautner, Finn; Holzer, Ursula; Schäfer, Jürgen Frank; Ebinger, Martin; Handgretinger, Rupert; Nahnsen, Sven; Rammensee, Hans-Georg; Lang, Peter. (2025). Case Report: A neoantigen-targeting peptide vaccine combined with checkpoint inhibition induces tumor regression and long-term remission in a pediatric patient with metastatic hepatocellular carcinoma.. Frontiers in immunology, 16, 1674663. https://doi.org/10.3389/fimmu.2025.1674663